HBM Healthcare Investments (Cayman) Ltd. - 14 Feb 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
10%+ Owner
Signature
/s/ Jean-Marc LeSieur, Managing Director
Issuer symbol
MLYS
Transactions as of
14 Feb 2023
Net transactions value
+$5,000,000
Form type
4
Filing time
16 Feb 2023, 20:00:28 UTC
Previous filing
09 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Conversion of derivative security +1,941,368 1,941,368 14 Feb 2023 Direct F1
transaction MLYS Common Stock Conversion of derivative security +964,238 +50% 2,905,606 14 Feb 2023 Direct F2
transaction MLYS Common Stock Purchase $5,000,000 +312,500 +11% $16.00 3,218,106 14 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Series A Preferred Stock Conversion of derivative security $0 -20,962,895 -100% $0.000000* 0 14 Feb 2023 Common Stock 1,941,368 Direct F1
transaction MLYS Series B Preferred Stock Conversion of derivative security $0 -10,411,846 -100% $0.000000* 0 14 Feb 2023 Common Stock 964,238 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

HBM Healthcare Investments (Cayman) Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.
F2 Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.